

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

FREEHILL MINING LIMITED

ABN

27 091 608 025

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- | | | |
|---|---|--|
| 1 | +Class of +securities issued or to be issued | (a) Fully paid ordinary shares.
(b) Options.
(c) Convertible notes. |
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued | (a) 334,668,350 fully paid ordinary shares.
(b) 166,481,086 options (Investor Options).
(c) 10,000,000 options (Director Options).
(d) 30,000,000 options (Lacerta Options).
(e) 248 convertible notes. |

For personal use only

- 3 Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)
- (a) Fully paid ordinary shares on the same terms as the existing fully paid ordinary shares on issue.
 - (b) Investor Options are options to acquire 1 fully paid ordinary share each are exercisable at \$0.025 per share and have an expiry date of 12 November 2021.
 - (c) Director Options are options to acquire 1 fully paid ordinary share each are exercisable at \$0.025 per share and have an expiry date of 12 November 2021.
 - (d) Lacerta Options are options to acquire 1 fully paid ordinary share each are exercisable at \$0.10 per share and have an expiry date of 12 November 2022.
 - (e) Convertible notes issued on the following terms:
 - i. Face value: \$1,000 per note
 - ii. Duration: term ending on 8 August 2022.
 - iii. Conversion: notes are convertible at any time with the term into fully paid ordinary shares in the Company at the lower of \$0.011 per share and a price which is 85% of the volume weighted average price of the Company's shares during the 7 days prior to the date of notice of conversion, excluding trades by the noteholder and its associates.
 - iv. Interest: the notes will accrue interest at a rate of 15% per annum, which may be paid in cash or in shares.
 - v. Redemption: notes may be redeemed during the term or at maturity if not previously converted.

+ See chapter 19 for defined terms.

<p>4 Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?</p> <p>If the additional +securities do not rank equally, please state:</p> <ul style="list-style-type: none">• the date from which they do• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	<p>(a) Yes, the shares rank equally with existing ordinary shares.</p> <p>(b) Shares issued upon exercise of Investor Options, Director Options and Lacerta Options will rank equally with existing ordinary shares.</p> <p>(c) Shares issued on conversion of convertible notes will rank equally with existing ordinary shares.</p>
<p>5 Issue price or consideration</p>	<p>(a) Fully paid ordinary shares:</p> <ol style="list-style-type: none">315,286,964 shares issued at a price of \$0.011 per share;3,333,333 shares issued at a price of \$0.015 per share;7,198,053 shares issued at a price of \$0.00972485 per share;8,850,000 shares issued for no cash consideration. <p>(b) Investor Options, Director Options and Lacerta Options are issued for nil consideration.</p> <p>(c) Convertible notes are issued at a price of \$1,000 per note.</p>
<p>6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)</p>	<p>(a) Fully paid ordinary shares:</p> <ol style="list-style-type: none">214,272,719 shares issued under a placement to professional and sophisticated investors as approved at the Company's General Meeting on 28 October 2019 (Resolution 1);4,787,880 shares issued in lieu of fees owing to the Company's CEO and Executive Director as approved at the Company's General Meeting on 28 October 2019 (Resolution 3(a));4,600,000 shares issued in respect of vested performance rights issued to the Company's CEO and Executive Director as approved at the Company's General Meeting on 28 October 2019 (Resolution 3(b));3,333,333 shares issued pursuant to a

- consultancy agreement between the Company and an entity nominated by the Company's CEO and Executive Director as approved at the Company's General Meeting on 28 October 2019 (Resolution 3(c));
- v. 2,142,613 shares issued on conversion of convertible notes issued to Yaniv Equity LP and accrued interest;
 - vi. 4,250,000 shares issued to Yaniv Equity LP pursuant to an agreement with the Company as approved at the Company's General Meeting on 28 October 2019 (Resolution 5(a));
 - vii. 6,300,000 shares issued to Non-Executive Directors of the Company in lieu of directors' fees as approved at the Company's General Meeting on 28 October 2019 (Resolutions 7(a) and 7(b));
 - viii. 3,272,727 shares issued to a director of the Company's wholly-owned Chilean subsidiaries in lieu of fees as approved at the Company's General Meeting on 28 October 2019 (Resolution 9);
 - ix. 32,325,557 shares issued to Non-Executive Directors of the Company in respect of the conversion of loan debt to equity as approved at the Company's General Meeting on 28 October 2019 (Resolutions 10(a) and 10(b));
 - x. 14,458,196 shares issued to sophisticated and professional investors on conversion of loan debt to equity as approved at the Company's General Meeting on 28 October 2019 (Resolution 11);
 - xi. 35,000,000 shares issued to sophisticated and professional investors in lieu of \$385,000 in professional fees owing in relation to the Company's acquisition of the Arenas XI mining tenements; and
 - xii. 9,925,325 shares issued to sophisticated and professional investors on conversion of loan debt into equity.

(b) Options:

+ See chapter 19 for defined terms.

- i. 107,136,361 Investor Options issued as attaching options to placement participants as approved at the Company's General Meeting on 28 October 2019 (Resolution 1);
 - ii. 1,984,725 Investor Options issued to Yaniv Equity LP as approved at the Company's General Meeting on 28 October 2019 (Resolution 5(b));
 - iii. 10,000,000 Director Options are issued to Mr Paul Davies, an Executive Director of the Company, under the Company's Equity Incentive Plan, as approved at the Company's General Meeting on 28 October 2019 (Resolution 8); and
 - iv. 57,360,000 Investor options issued to nominees of CPS Capital Group Pty Ltd as payment for broking services provided in relation to the Company's placement.
- (c) 30,000,000 Lacerta Options issued to nominees of Lacerta Mining & Finance SpA as approved at the Company's General Meeting on 28 October 2019 (Resolution 12).
- (d) 248 convertible notes are issued to professional and sophisticated investors as approved at the Company's General Meeting on 28 October 2019 (Resolution 14).

6a	<p>Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?</p> <p>If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i</p>	No.
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of *securities issued without security holder approval under rule 7.1	<p>(a) 44,925,325 fully paid ordinary shares.</p> <p>(b) 5,360,000 Investor Options.</p>
6d	Number of *securities issued with security holder approval under rule 7.1A	Nil.

6e	Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	<p>(a) 287,600,412 fully paid ordinary shares as (security holder approval obtained at General Meeting on 28 October 2019).</p> <p>(b) 161,121,086 Investor Options (security holder approval obtained at General Meeting on 28 October 2019).</p> <p>(c) 10,000,000 Director Options (security holder approval obtained at General Meeting on 28 October 2019).</p> <p>(d) 30,000,000 Lacerta Options (security holder approval obtained at General Meeting on 28 October 2019).</p> <p>(e) 248 convertible notes (security holder approval obtained at General Meeting on 28 October 2019).</p>
6f	Number of +securities issued under an exception in rule 7.2	2,142,613 fully paid ordinary shares.
6g	If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.	N/A
6h	If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	7.1 Capacity: 115,582,721 7.1A Capacity: N/A
7	<p>+Issue dates</p> <p>Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.</p> <p>Cross reference: item 33 of Appendix 3B.</p>	12 November 2019

+ See chapter 19 for defined terms.

	Number	+Class
8	1,150,942,300	Fully Paid Ordinary Shares
	166,481,086	Options to acquire one fully paid ordinary share each, exercisable at \$0.025, expiring on 12 November 2021.

	Number	+Class
9	1,000,000	Performance rights issued on 6 February 2017 to the Company COO.
	248	Convertible Notes with a value of \$1,000 per note issued on 12 November 2019, convertible at the lesser of \$0.011 and a price which is 85% of the 7-trading day volume weighted average price of the Company's shares prior to the date of notice of conversion, excluding trades made by the converting noteholder.

12	Convertible Notes issued on 21 December 2018, convertible at \$0.015 per share if converted before 15 February 2019, or at a price which is 85% of the 7-trading day volume weighted average price of the Company's shares prior to the date of notice of conversion, excluding trades made by the converting noteholder.
50	Convertible Notes issued on 28 February 2019, convertible at a price which is 85% of the 7-trading day volume weighted average price of the Company's shares prior to the date of notice of conversion, excluding trades made by the converting noteholder.
1,984,725	Options exercisable at \$0.1425 vesting 16 May 2018 and expiring on 16 May 2023.
10,000,000	Options to acquire one fully paid ordinary share each, exercisable at \$0.025, expiring on 12 November 2021.
30,000,000	Options exercisable at \$0.10 vesting 12 November 2019 and expiring on 12 November 2022.

+ See chapter 19 for defined terms.

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

The Board of the Company may from time to time determine to distribute the profits of the Company by way of dividend amongst the Shareholders in proportion to the amounts paid up on the Shares held by them.

Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the +securities will be offered	N/A
14	+Class of +securities to which the offer relates	N/A
15	+Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents <small>Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.</small>	N/A
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A

+ See chapter 19 for defined terms.

For personal use only

24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	*Issue date	N/A

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of +securities
(tick one)

(a) +Securities described in Part 1 – all fully paid ordinary shares and 166,481,086 Investor Options.

(b) All other +securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35 If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders

36 If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories

1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over

37 A copy of any trust deed for the additional +securities

Entities that have ticked box 34(b)

38 Number of +securities for which +quotation is sought

39 +Class of +securities for which quotation is sought

+ See chapter 19 for defined terms.

For personal use only

40 Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?

If the additional +securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

--

41 Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another +security, clearly identify that other +security)

--

42 Number and +class of all +securities quoted on ASX (including the +securities in clause 38)

Number	+Class

Quotation agreement

1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.

- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:



Date: 13 November 2019

Print name: Paul Davies

== == == == ==

+ See chapter 19 for defined terms.

For personal use only

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital	
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated	
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	405,766,034
<p>Add the following:</p> <ul style="list-style-type: none"> • Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2 • Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval • Number of partly paid +ordinary securities that became fully paid in that 12 month period <p><i>Note:</i></p> <ul style="list-style-type: none"> • <i>Include only ordinary securities here – other classes of equity securities cannot be added</i> • <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i> 	<p>19,041,952 fully paid ordinary shares (Issued 29 November 2018, Rule 7.4)</p> <p>53,031,164 fully paid ordinary shares (Issued 6 December 2018, Rule 7.2, Exception 1)</p> <p>9,845,709 fully paid ordinary shares (Issued 14 December 2018, Rule 7.4)</p> <p>12,251,111 fully paid ordinary shares (Issued 14 December 2018, Rule 7.2, Exception 14)</p> <p>29,345,968 fully paid ordinary shares (Issued 24 December 2018, Rule 7.4)</p> <p>8,079,105 fully paid ordinary shares (Issued 24 December 2018, Rule 7.3)</p> <p>28,333,331 fully paid ordinary shares (Issued 24 December 2018, Rule 7.2, Exception 3)</p> <p>3,658,948 fully paid ordinary shares (Issued 31 December 2018, Rule 7.4)</p> <p>13,333,334 fully paid ordinary shares (Issued 31 December 2018, Rule 7.2, Exception 3)</p> <p>61,727,746 fully paid ordinary shares (Issued 31 December 2018, Rule 7.2, Exception 14)</p> <p>727,481 fully paid ordinary shares (Issued 7 January 2019, Rule 7.3)</p> <p>2,784,291 fully paid ordinary shares (Issued 7 January 2019, Rule 7.2, Exception 4)</p> <p>7,147,058 fully paid ordinary shares (Issued</p>

+ See chapter 19 for defined terms.

For personal use only

	<p>28 February 2019, Rule 7.2, Exception 4)</p> <p>3,200,000 fully paid ordinary shares (Issued 28 February 2019, Rule 7.2, Exception 3)</p> <p>3,967,476 fully paid ordinary shares (Issued 4 March 2019, Rule 7.2, Exception 4)</p> <p>18,181,731 fully paid ordinary shares (Issued 6 March 2019, Rule 7.2, Exception 4)</p> <p>20,571,122 fully paid ordinary shares (Issued 8 March 2019, Rule 7.4)</p> <p>75,686,570 fully paid ordinary shares (Issued 8 March 2019, Rule 7.2, Exception 4)</p> <p>19,093,800 fully paid ordinary shares (Issued 12 March 2019, Rule 7.2, Exception 4)</p> <p>8,333,334 fully paid ordinary shares (Issued 12 March 2019, Rule 7.4)</p> <p>6,000,000 fully paid ordinary shares (Issued 16 April 2019, Rule 7.4)</p> <p>5,494,506 fully paid ordinary shares (Issued 17 May 2019, Rule 7.2, Exception 4)</p> <p>287,600,412 fully paid ordinary shares (Issued 12 November 2019, Rule 7.3)</p> <p>2,142,613 fully paid ordinary shares (Issued 12 November 2019, Rule 7.2, Exception 4)</p>
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period	Nil.
“A”	1,105,986,974

Step 2: Calculate 15% of “A”	
“B”	0.15 <i>[Note: this value cannot be changed]</i>
Multiply “A” by 0.15	165,898,046
Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used	
Insert number of +equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	30,000 fully paid ordinary shares (8 March 2019) 5,360,000 options exercisable at \$0.025 per

+ See chapter 19 for defined terms.

<ul style="list-style-type: none"> • Under an exception in rule 7.2 • Under rule 7.1A • With security holder approval under rule 7.1 or rule 7.4 <p><i>Note:</i></p> <ul style="list-style-type: none"> • <i>This applies to equity securities, unless specifically excluded – not just ordinary securities</i> • <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i> 	<p>option, expiring 12 November 2021 (12 November 2019)</p> <p>44,925,325 fully paid ordinary shares (12 November 2019)</p>
“C”	50,315,325
Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1	
<p>“A” x 0.15</p> <p><i>Note: number must be same as shown in Step 2</i></p>	165,898,046
<p>Subtract “C”</p> <p><i>Note: number must be same as shown in Step 3</i></p>	50,315,325
<p>Total [“A” x 0.15] – “C”</p>	<p>115,582,721</p> <p><i>[Note: this is the remaining placement capacity under rule 7.1]</i></p>

+ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities	
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated	
“A” <i>Note: number must be same as shown in Step 1 of Part 1</i>	N/A
Step 2: Calculate 10% of “A”	
“D”	0.10 <i>Note: this value cannot be changed</i>
Multiply “A” by 0.10	N/A
Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used	
Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A Notes: <ul style="list-style-type: none"> • <i>This applies to equity securities – not just ordinary securities</i> • <i>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i> 	N/A
“E”	N/A

+ See chapter 19 for defined terms.

For personal use only

Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A	
<p>“A” x 0.10</p> <p><i>Note: number must be same as shown in Step 2</i></p>	N/A
<p>Subtract “E”</p> <p><i>Note: number must be same as shown in Step 3</i></p>	N/A
<p>Total [“A” x 0.10] – “E”</p>	<p>N/A</p> <p><i>Note: this is the remaining placement capacity under rule 7.1A</i></p>

+ See chapter 19 for defined terms.